Presidential Memorandum on Prescription Drug Advertisements

On September 10, 2025, President Donald J. Trump signed a Presidential Memorandum aimed at increasing transparency and accuracy in direct-to-consumer prescription drug advertisements. The memorandum instructs the Secretary of Health and Human Services to enhance the information provided in these advertisements, particularly regarding the associated risks of prescription drugs. Additionally, the Food and Drug Administration is charged with enforcing legal requirements to ensure that these advertisements are truthful and not misleading.

The article highlights the substantial financial investment pharmaceutical companies make in direct-to-consumer advertising, which exceeded $10 billion in 2024. It points out that the United States is one of only two countries that allow such advertising, raising concerns about its potential to mislead consumers and affect the patient-physician relationship. The President’s actions are intended to alleviate the negative impacts of these advertisements by fostering a more informed consumer base.

Furthermore, President Trump emphasizes his commitment to prioritizing Americans and ensuring that healthcare practices focus on patient welfare. In addition to the recent memorandum, he has previously signed executive orders aimed at reducing prescription drug prices and increasing transparency in healthcare pricing. Together, these efforts reflect a broader strategy to enhance patient protection and accountability within the pharmaceutical industry.

Original: article